SELECT Trial Explained: What Semaglutide's 20% Heart Result Really Means

Evidence guide · Last verified August 3, 2026 · By Weight Loss Provider Guide

Weight Loss Provider Guide is an independent comparison and information resource for GLP-1 telehealth providers. Advertising disclosure

The SELECT trial explained, in one paragraph: 17,604 adults age 45 or older who had established cardiovascular disease, a BMI of 27 or higher, and no diabetes were assigned to weekly Wegovy injection or placebo and followed for a mean of 39.8 months. A first cardiovascular death, nonfatal heart attack, or nonfatal stroke happened in 6.5% of the Wegovy group and 8.0% of the placebo group. The published “20% reduction” comes from the trial's hazard ratio of 0.80; the crude absolute difference was 1.5 percentage points, which translates to a simple NNT of about 67 similar patients over the study period. Three things change how directly that result applies to you: whether you have diabetes, whether your cardiovascular history resembles the trial's entry criteria, and whether you are considering the weekly Wegovy injection that SELECT directly tested. (Primary SELECT report)

That's the answer. You can stop reading here if that's all you needed.

But here's the thing that took us the longest to untangle, and it's the reason this page exists. The trial, the current FDA label, and your insurance rules are three different layers. The trial had strict rules about who could join. The current label is not written with identical boundaries. Your plan can add its own formulary and prior-authorization requirements on top of both. Mixing those three layers is how a clean clinical result turns into a denial, a misleading sales pitch, or both.

We'll get there. First, the numbers.

The 60-second version

Source: Lincoff AM et al., New England Journal of Medicine, 2023. The absolute risk difference, per-10,000 translation, and simple NNT are our calculations from the published event proportions. We show the arithmetic below.

Before we sell you on anything: the part that isn't great

We're going to say some genuinely impressive things about this trial. So let's start with the two facts that get left out of almost every article about it.

One. The famous mortality finding was never formally confirmed. Cardiovascular death was the first confirmatory secondary endpoint — the next result in line to be officially tested after the main one. It came in at a hazard ratio of 0.85, with a 95% confidence interval of 0.71 to 1.01 and a P value of 0.07 against the trial's stricter allocated threshold. It missed. Because the prewritten testing sequence stopped there, the all-cause death result farther down the hierarchy could not be declared statistically significant under that confirmatory sequence, even though its point estimate looked favorable. Most consumer articles quote the flattering numbers without explaining that distinction. We won't.

Two. Side effects were not a footnote. Adverse events caused 16.6% of people assigned semaglutide to permanently stop the trial product, versus 8.2% assigned placebo. Gastrointestinal problems drove much of that difference. That's roughly one additional person in twelve who stopped because of an adverse event.

Now here's why we still take this trial seriously, and why you probably should too.

A trial report that does not hide or spin away a failed confirmatory endpoint is more credible than a page that quotes only the flattering numbers. Novo Nordisk funded SELECT. The endpoint order and statistical rules were set before the result was known. The paper and current FDA label both state that cardiovascular death was not confirmed under the prespecified hierarchy. (Current FDA-approved prescribing information)

And the main result — cardiovascular death, nonfatal heart attack, and nonfatal stroke combined — held cleanly at a bar set before the data existed. That primary MACE result was the core efficacy result behind FDA's 2024 cardiovascular indication. That's the number worth understanding.

SELECT trial explained: what did it actually find?

Answer capsule: In SELECT, a first major cardiovascular event happened in 569 of 8,803 people assigned semaglutide (6.5%) and 701 of 8,801 assigned placebo (8.0%), a hazard ratio of 0.80 (95% CI 0.72–0.90, P<0.001). “Major cardiovascular event” meant cardiovascular death, a nonfatal heart attack, or a nonfatal stroke. Mean follow-up was 39.8 months. (Primary SELECT report)

What counted as an “event”

Trials like this one bundle several bad outcomes into a single score. Researchers call it a composite endpoint. SELECT used three:

• Death from a cardiovascular cause
• A nonfatal heart attack
• A nonfatal stroke

If any one of those happened first, it counted toward the primary endpoint. Bundling gives a trial more events to analyze in a reasonable timeframe. The catch is that a good bundled result doesn't automatically mean all three parts improved equally. We break the parts out below.

The same result, at three different scales

Percentages are slippery. Here's what the crude reported proportions look like in actual people:

That's a straight translation of the reported group percentages over the study period. It is not a prediction about you.

Why you'll see 20% and 18.75% and both calculations are defensible

This one confuses everybody, including some doctors.

Divide the raw percentages and you get a different answer than the published headline:

• Raw proportion math: 6.5 ÷ 8.0 = 0.8125, so an 18.75% crude relative difference
• Published headline: 1 − 0.80 (the hazard ratio) = 20%

Both calculations can be correct because they're answering slightly different statistical questions. The raw calculation compares the reported final proportions. The hazard ratio comes from a time-to-event model that compares how first events accumulated during follow-up while accounting for unequal observation time and censoring.

Nobody needs to be fudging anything for both numbers to appear. But if you've been staring at 6.5 versus 8.0 wondering how anyone got 20 out of that, now you know.

What you can accurately say: In SELECT's population, weekly semaglutide lowered the hazard of a first major cardiovascular event by 20% compared with placebo.

What you can't say: “Semaglutide prevents 20% of heart attacks.” “Twenty out of every hundred people were saved.” “GLP-1 drugs cut heart risk 20% for everyone.” All three overstate what SELECT showed.

What happened to heart attacks, strokes, cardiovascular death, and heart failure separately?

Answer capsule: The primary three-part MACE result was statistically robust, and the myocardial-infarction result was numerically and statistically favorable. Cardiovascular death alone had a favorable point estimate but was not confirmed under the prespecified hierarchy, while stroke and the heart-failure endpoint had confidence intervals that included no difference.

The bundle matters. So do the parts.

Component outcomes and testing labels: current FDA-approved Wegovy prescribing information.

This table is why “heart attacks, strokes, and deaths all fell by 20%” is wrong. The 20% belongs to the time-to-first composite. The pieces did not all move by the same amount or with the same certainty.

It also shows why the damaging admission above matters. The cardiovascular-death point estimate looked good. The all-cause-death point estimate looked good. But the trial's confirmatory rules were stricter than “the number went in the right direction,” and the page should be too.

What does a 20% reduction mean for one actual person?

Answer capsule: The crude absolute difference in SELECT was 1.5 percentage points (8.0% minus 6.5%). Dividing 1 by 0.015 gives a simple number-needed-to-treat estimate of about 67 similar people for one first major cardiovascular event avoided over the roughly 3.3-year mean follow-up. Over the same study period, adverse events caused 16.6% of the semaglutide group to stop the trial product versus 8.2% on placebo. (Published event counts)

Here's the arithmetic, out in the open:

Absolute difference:   8.0% − 6.5% = 1.5 percentage points
Simple NNT:            1 ÷ 0.015 = 66.7, so about 67
Per 10,000 people:     800 events vs. 650 events = 150 fewer
Relative (hazard):     1 − 0.80 = 20%

An important caveat, stated plainly: this is a crude NNT calculated from the published group proportions over a mean follow-up of 39.8 months. SELECT used time-to-event methods, and people were followed for different lengths of time. Treat 67 as a useful rough translation, not a fixed-time Kaplan–Meier NNT or a personal forecast.

The comparison the headline needs beside it

We put these two trial numbers side by side because a reader making a real decision needs both:

Over the study period, the crude proportions suggest roughly 1 first MACE avoided for every 67 similar people treated. Over that same trial, the excess adverse-event discontinuation was roughly 1 additional person for every 12 treated.

Both numbers come from SELECT. Both are real. Neither cancels the other out.

They are also not the same kind of outcome. One is a rough translation of a first cardiovascular event prevented. The other is stopping the trial product because of an adverse event. A discontinuation is not equivalent to a heart attack, stroke, or cardiovascular death, and this is not a “benefit versus harm score.” It is the clearest way to show that preventive benefit and tolerability have to be judged together.

Read cynically, the numbers can look lopsided. Read carefully, they show the basic shape of prevention: many people accept a treatment so that a smaller number avoid an event no one can identify in advance. The people who benefit never get a receipt saying which event did not happen. That's why baseline risk, tolerability, cost, and the rest of your cardiovascular care matter so much.

Is an NNT of about 67 good or bad?

Depends entirely on the person. What moves the real-world calculation:

• Your starting risk. The higher your baseline chance of an event, the more absolute benefit the same relative effect can produce. Everyone in SELECT had established cardiovascular disease.
• How long you stay on it. The rough NNT is tied to this study's duration and follow-up, not one month, one year, or a lifetime.
• What else changes. SELECT also reported secondary or supportive changes in weight, blood pressure, lipids, glycemia, and kidney outcomes. Those do not all carry the same evidentiary weight as the primary MACE result.
• What you can tolerate. A favorable average does not help someone who cannot continue treatment safely.
• What it costs you. Both money and hassle count.
• What treatment you are already receiving. SELECT added semaglutide to standard cardiovascular care. It did not replace it.

What readers are actually asking

We pulled these from public discussion threads to show where people get stuck. They are questions, not medical evidence:

“I doubt they're lying outright, but show me the data.” (Source thread)

“What do averages calculated on only 10% of participants mean?” (Source thread)

The first one is why every central number on this page maps to a named source. The second is a great question with a genuinely surprising answer, and we've given it its own section below.

→ Check how closely you match the people in SELECT
Compare your age, cardiovascular history, BMI, and diabetes status with the actual trial entry rules. No email is required to see the result. Nothing is being sold inside the tool.

Who was in the SELECT trial?

Answer capsule: SELECT enrolled adults age 45 or older with a BMI of at least 27 who had established cardiovascular disease — a prior heart attack, prior stroke, or symptomatic peripheral artery disease — and who did not have type 1 or type 2 diabetes. The average participant was about 62 years old with a BMI of about 33, and 72% were men. (FDA clinical-study summary)

Who got in

Four gates. You had to clear all of them:

• Age 45 or older
• BMI 27 or higher
• A prior heart attack, a prior stroke, or symptomatic peripheral artery disease
• No history of type 1 or type 2 diabetes and no screening A1c at or above 6.5%

That third gate is stricter than most people realize. “Established cardiovascular disease” in SELECT did not mean high cholesterol. It did not mean a family history. It did not mean that every possible heart diagnosis qualified. One of the trial's specified cardiovascular gateways had to be present.

Who got kept out

Major exclusions included:

• A heart attack, unstable angina, stroke, or transient ischemic attack in the prior 60 days
• A planned coronary, carotid, or peripheral revascularization
• NYHA class IV heart failure
• End-stage kidney disease or dialysis
• Type 1 or type 2 diabetes, or screening A1c at or above 6.5%
• Use of another GLP-1 receptor agonist within 90 days
• Acute pancreatitis within 180 days or chronic pancreatitis
• A personal or first-degree family history of medullary thyroid carcinoma or MEN 2

Those are protocol boundaries, not a substitute for the current prescribing information or a clinician's judgment.

What the average participant looked like

The fact that changes how you read the entire trial

Most SELECT participants were already receiving serious cardiovascular treatment at baseline:

The 20% lower hazard was measured on top of that background care. Not instead of it.

This is one of the most misread things about SELECT, and it cuts both ways. It means the primary benefit appeared even in a population receiving substantial modern cardiovascular treatment, which is impressive. And it means nothing in SELECT supports reducing or stopping a statin, blood-pressure medication, antiplatelet drug, or other clinician-directed cardiovascular treatment because semaglutide was added. If you take one thing from this section, take that.

Where the trial is thin

We're not going to pretend otherwise:

• Women were 27.7% of participants. A later sex analysis found no statistically significant treatment-by-sex interaction for MACE, but the confidence interval for women was wider. A smaller group means less precision, not proof that the effect is identical.
• Black participants were about 4%. That is a real limitation. The long-term analysis said the study lacked the numbers in racial subgroups needed to reveal possible differences in treatment effect with confidence.
• Nobody under 45 was enrolled.
• Nobody without established cardiovascular disease was enrolled.
• Nobody with diabetes at baseline was enrolled.

None of that makes the result invalid. It makes it specific. Which brings us to the tool.

Would you have qualified for SELECT?

Answer capsule: SELECT's core entry rules were age 45 or older, BMI 27 or higher, a prior heart attack, prior stroke, or symptomatic peripheral artery disease, and no diabetes. A trial-similarity tool can show where your profile matches or differs, but it cannot decide whether you meet the current FDA label, qualify for insurance coverage, or should take Wegovy.

Use this four-question check to compare your profile with the trial's core entry criteria. The logic is visible even before you use the interactive version.

How closely do you match SELECT?

→ Compare my profile with SELECT

Read your evidence fit this way:

If all four answers match: you closely resemble SELECT's core entry criteria. The main result is more directly relevant to your profile than it is to the general weight-loss population. That still does not predict your personal benefit, establish medical suitability, or guarantee coverage. Take the clinician questions later on this page to your appointment.

If one or more answers differ: you differ from SELECT on a core criterion. The exact line that differs weakens direct applicability. The current FDA label, a different semaglutide trial, or another evidence base may still matter, but a four-question comparison cannot decide that for you.

If you have no established cardiovascular disease, are under 45, have a BMI below 27, or have diabetes: SELECT is not the direct evidence base for that part of your profile. That's not a dead end. It means you need the evidence that actually matches your situation instead of stretching this trial until it breaks.

This is not a medical or insurance eligibility check. It mirrors selected trial criteria. It cannot tell you whether a medication is safe, appropriate, covered, or likely to help you personally. Your clinician and plan make those decisions.

Why do the four-year SELECT charts show so few people?

Answer capsule: SELECT enrolled people over multiple years and ended on an event-driven schedule, so only earlier enrollees had the opportunity to reach week 208. Trial follow-up completion remained about 97% in both groups, even though 30.6% of the semaglutide group and 27.0% of the placebo group did not complete assigned treatment. (Long-term SELECT analysis)

If you've looked at the long-term weight charts and noticed the number under the graph shrinking week by week, you've spotted something real. And the conclusion most people jump to is wrong.

Four different things get confused with each other

This is where nearly every online explanation goes sideways. There are four separate reasons a person might not appear in a week-208 weight number, and they mean completely different things:

1. They did not have the opportunity to reach week 208 before the event-driven trial ended. SELECT enrolled from October 2018 through March 2021 and completed in 2023. Someone enrolled early could accumulate four years. Someone enrolled later could complete trial follow-up without ever reaching the week-208 landmark. They did not necessarily drop out. The available calendar time was shorter.

2. They stopped the medication but stayed in trial follow-up. These people could still contribute cardiovascular outcome data because the primary analysis followed people by the group they were randomly assigned to. That's intention-to-treat analysis, and it protects the value of randomization.

3. They missed a weight measurement. A missing measurement at one time point is not automatically a missing participant.

4. They were truly lost to trial follow-up. This is the category most readers assume every shrinking denominator represents. It was much smaller than the number who stopped assigned treatment.

The three numbers that settle it

Both things are true at once, and they're not in conflict. Staying in a trial and staying on a drug are different measurements. Most people stayed in follow-up. A meaningful minority stopped assigned treatment. The cardiovascular analysis still followed outcomes by randomized group.

About the long-term weight numbers

The week-208 weight analysis reported modeled estimates and used multiple imputation to address missing observations. The investigators generated 500 imputed datasets. Multiple imputation is a standard statistical method. It also depends on assumptions about missing data.

The long-term paper reported an estimated mean weight change at week 208 of −10.2% with semaglutide versus −1.5% with placebo under its in-trial estimand. Its on-treatment estimate was larger. Neither should be described as if all 17,604 randomized participants stepped on a scale at week 208.

And the long-term result should not be dismissed as fake, either. It is a modeled estimate reported with a defined method. The right response is to label the denominator, the estimand, and the imputation — not to pretend the data are simpler than they are.

The honest summary: much of the shrinking week-208 denominator reflects unequal opportunity to reach that landmark plus missing measurements, not a mass disappearance from outcome follow-up. But treatment discontinuation was real, and it was substantial.

What the SELECT trial did not prove

Answer capsule: SELECT studied secondary prevention in people with established cardiovascular disease, so it does not establish prevention of a first cardiovascular event in the general overweight or obesity population. It excluded diabetes at baseline, directly tested weekly Wegovy injection rather than every semaglutide formulation, and did not establish the exact mechanism of cardiovascular risk reduction.

Five limits worth knowing.

It wasn't a primary-prevention trial for people with no established cardiovascular disease

SELECT was a secondary-prevention trial. Participants had established cardiovascular disease through prior heart attack, prior stroke, or symptomatic peripheral artery disease. The long-term investigators cautioned against extrapolating the result to everyone with overweight or obesity for cardiovascular prevention. When the researchers draw that line, everybody else should respect it.

It didn't study people with diabetes at baseline

Diabetes was excluded on purpose. Much of the earlier GLP-1 cardiovascular-outcomes evidence came from people with type 2 diabetes. SELECT answered a different question: whether semaglutide could reduce MACE in people with established cardiovascular disease and overweight or obesity without diabetes. That's a strength of the design and a limit on who this trial speaks for directly.

It doesn't prove the benefit came from weight loss — and that's the interesting part

A prespecified analysis published in The Lancet in 2025 examined treatment effects across baseline adiposity and measured weight-change categories. The MACE benefit was not confined to the people with the highest starting BMI or the greatest measured weight loss. In a mediation analysis, change in waist circumference was estimated to account for about one-third of the observed treatment effect. (Prespecified adiposity analysis)

A related descriptive analysis noted that the event curves began separating early while average weight change was already different between groups. That timing does not prove a mechanism. Nor does categorizing people by weight change after randomization preserve the same clean causal interpretation as the randomized treatment comparison.

Here's the answer to the question a lot of you came with: the group-level cardiovascular benefit was not limited to participants who lost the most weight.

Here's what that does not mean: it does not guarantee benefit for an individual who loses little or no weight. It does not prove the effect has nothing to do with weight. It does not prove that inflammation, “direct vascular protection,” or any single pathway caused the result. The current Wegovy label states directly that the exact mechanism of cardiovascular risk reduction has not been established. Anyone naming one proven mechanism is going farther than the evidence.

It did not establish a heart-failure indication

A prespecified analysis found generally favorable cardiovascular outcomes in participants with and without baseline heart failure and across preserved- and reduced-ejection-fraction categories. The current FDA label still states that the effect of Wegovy on heart failure has not been established.

Both statements can be true. A supportive subgroup analysis and an established labeled effect are different categories, and we're not going to blur them.

It doesn't transfer automatically to other drugs or other versions

SELECT directly tested once-weekly subcutaneous semaglutide, titrated toward a target dose of 2.4 mg. Not tirzepatide. Not compounded semaglutide. Not every oral or injectable product containing or related to semaglutide. Not a class of drugs. Each one gets its own section below because each has a different evidence answer.

Why SELECT changed what insurance may cover

Answer capsule: On March 8, 2024, FDA approved Wegovy to reduce cardiovascular death, nonfatal heart attack, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight. That created a Part D coverage pathway for the cardiovascular indication and a commercial-insurance argument that did not exist when Wegovy was treated only as a weight-management drug, but coverage still depends on the current label, the plan's formulary, prior-authorization rules, and the diagnosis being treated. (FDA approval announcement)

This is the part with real money attached, and it's where three documents that look similar can send you in three different directions.

The trial and the current label are not identical

We put them side by side, then added the payer question the other two documents cannot answer for you.

Read that table twice. A person can fit the current label without reproducing SELECT's exact protocol. That does not mean SELECT gives equally direct evidence for every person the label may cover.

That's not a scandal. FDA reviewed a full application, not one headline. But it has a practical consequence: the farther your profile moves from the directly studied population or formulation, the more important it becomes to separate “approved,” “directly studied,” “medically appropriate,” and “covered.” They are not synonyms.

The gap cannot be reduced to one clean population number

It is tempting to subtract two published estimates and call the difference a measured “trial-to-label gap.” That arithmetic does not hold because the studies used different definitions and could not measure the same cardiovascular gateways.

Here is the source-audited version, using the Lusk estimate and the separate JAMA Cardiology eligibility analysis:

These estimates do not contradict each other. They answer different questions. Do not subtract them and pretend the remainder is a verified trial-to-label population. The original insight still survives: millions of US adults may be touched by the cardiovascular indication, and a large group will not look exactly like the randomized SELECT population. The honest version keeps the denominators attached.

What your plan actually asks for

Insurers and Part D plans set their own formularies and prior-authorization rules. A plan may ask for:

• Documentation of established cardiovascular disease in the medical record
• Documentation that the patient has obesity or overweight
• The exact product and formulation requested
• A prescription and clinical rationale tied to an FDA-approved indication
• Previous treatment, contraindication, or monitoring information
• Prior authorization, step therapy, or a formulary exception

The diagnosis and indication matter, especially in Medicare, but they are not the only things deciding a claim. Same drug, same person, same dose can still produce different outcomes under different plans, formularies, and documentation.

The one thing worth doing this week

If you've had a heart attack, a stroke, or symptomatic PAD and you have overweight or obesity, the highest-value ten minutes you can spend right now is finding out what your plan requires. Not what plans generally require. Yours.

A note on where we stand before the link: Weight Loss Provider Guide has an affiliate relationship with Ro and may earn a commission if you later begin treatment through Ro. The coverage report itself is currently offered free.

Ro's GLP-1 Insurance Coverage Checker currently checks coverage for the Ozempic pen, Wegovy pen, and Zepbound autoinjector pen. You enter the information from your insurance card; Ro says its insurance specialists contact the plan and email a personalized report that can include coverage explanations, possible cost information, and whether prior authorization is required. The checker does not submit a treatment request or write a prescription, and it does not currently check the Wegovy pill, Foundayo pill, or Zepbound KwikPen.

→ Check commercial insurance coverage for the Wegovy pen

If you'd rather not use it, call the member-services number on your insurance card or ask your prescriber's office to run a benefits investigation. That is slower, not inferior.

One person's experience with Ro's process, quoted from Ro's own coverage report, was: “When I went to CVS to pick up my prescription, it was just $25.”

Disclosure: Ro labels this person a paid partner. The quote comes from Ro's marketing materials, and we may earn a commission if you later use Ro. It describes one person's insurance and savings-card outcome. It is not a typical-price promise, it does not establish medical benefit, and your copay may be entirely different.

If you're the wrong reader for this section

We'd rather lose you here than waste your time:

• No diagnosed cardiovascular disease? This cardiovascular pathway may not fit. The weight-management coverage route is a different conversation. → How to get a GLP-1 approved for weight loss
• Have type 2 diabetes? SELECT is not the direct trial for your population, and diabetes indications and coverage rules may be more relevant. → Best GLP-1 options with diabetes
• Already denied Wegovy? Don't start over — start with the denial reason and the appeal requirements. → Wegovy prior-authorization guide
• On Medicare? Stop here before using a commercial checker. The Part D and Bridge routes are explained below. → Jump to the Medicare section

Does SELECT apply to compounded semaglutide?

Answer capsule: No. SELECT directly tested Wegovy injection, an FDA-approved product made to an approved specification. Compounded semaglutide products are not FDA-approved or reviewed before marketing for safety, effectiveness, or quality, and we found no randomized cardiovascular-outcomes trial of a compounded semaglutide product through the August 3, 2026 data cutoff. (FDA on unapproved GLP-1 products)

Let's be direct, because this is where a lot of pages get slippery.

A cardiovascular-outcomes result is attached to the product, formulation, dose strategy, population, and protocol that were studied. It is not a free-floating property that automatically transfers to every preparation described with a similar drug name. SELECT directly tested once-weekly Wegovy injection titrated toward 2.4 mg.

Compounded drugs may be prepared under federal-law conditions by licensed pharmacists, physicians, or registered outsourcing facilities. FDA does not approve compounded drugs and does not review them before marketing for safety, effectiveness, or quality. FDA also says a compounded drug should be used only when a patient's medical need cannot be met by an available FDA-approved drug.

That's not us being snobby about brands. The value of a trial like SELECT is knowing what product was used, how it was made, how it was dosed, and what was measured. You cannot preserve the outcome claim while discarding those controls.

Where the compounded semaglutide market stands right now

Some quick history, because it explains why your options may look different than they did in 2023 and 2024:

• February 21, 2025 — FDA determined that the shortage of semaglutide injection products was resolved.
• April 22, 2025 — FDA's announced enforcement-discretion window tied to the shortage ended for state-licensed pharmacies or physicians compounding under section 503A, subject to the agency's litigation language at the time.
• May 22, 2025 — the corresponding announced window ended for 503B outsourcing facilities.
• After the shortage windows — compounders remained responsible for every other statutory requirement. Patient-specific compounding may still be lawful in limited circumstances, but making products that are essentially copies of an available approved drug is restricted outside the statutory exceptions.
• April 30, 2026 — FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk substances. As of August 3, 2026, that was a proposal, not a final rule. The shortage-list pathway is legally separate.

The broad shortage-era market is substantially narrower now. That does not mean every compounded prescription is unlawful. It means “the shortage lets anyone sell a copy” is no longer an accurate description of the federal landscape.

What the FDA-approved brand currently costs

We're naming the manufacturer's own channel even though we earn nothing from it, because leaving it out would make everything else on this page less trustworthy. Prices and limited-time offers below were rechecked August 3, 2026 against the manufacturer's April 2026 price guide.

So why use Ro at all if NovoCare doesn't charge a membership?

Straight answer: Ro is not the cheapest service route if you already have a prescriber, already know your coverage, and can manage the paperwork yourself. NovoCare's cash medication price does not add Ro's membership fee.

What Ro sells is the service layer: evaluation by a licensed provider if appropriate, ongoing support, side-effect and dose-adjustment support, insurance checking for select pens, and prior-authorization handling when treatment is prescribed through the program. Ro currently says its FDA-approved cash-pay medication prices match manufacturer channels, but the membership is an additional charge.

For a reader with a cardiovascular history who needs a prescriber and help navigating a prior authorization, that service may solve the actual bottleneck. If it is not your bottleneck, go direct and save the membership cost. We'd rather tell you that than pretend.

→ See Ro's current membership and Wegovy pricing

Affiliate disclosure: we may earn a commission if you begin treatment through Ro. Medication is prescribed only if a Ro-affiliated provider determines it is appropriate. The current $39 first-month price does not include medication.

Does SELECT apply to Ozempic, Zepbound, Mounjaro, or the Wegovy pill?

Answer capsule: SELECT directly tested weekly Wegovy injection, not Ozempic, tirzepatide, compounded semaglutide, or Wegovy tablets. The current FDA label gives both Wegovy injection and Wegovy tablets the cardiovascular MACE indication, but the tablet's evidence and approval package are separate from the injection-only SELECT trial.

About tirzepatide, since everyone asks

Tirzepatide has completed a large cardiovascular-outcomes trial called SURPASS-CVOT. 13,299 people were randomized, and 13,165 remained in the modified intention-to-treat analysis. They had type 2 diabetes and atherosclerotic cardiovascular disease. Tirzepatide was compared with dulaglutide, not placebo.

A first MACE occurred in 12.2% with tirzepatide and 13.1% with dulaglutide, hazard ratio 0.92. That point estimate is about 8% lower, but the trial was designed first to test noninferiority. Tirzepatide met noninferiority; it did not demonstrate superiority over dulaglutide under the reported test. (Primary SURPASS-CVOT report)

That's a diabetes population and an active-comparator design. Different question, different answer.

The study closer to SELECT's no-diabetes, placebo-controlled obesity question is SURMOUNT-MMO. Its public trial record lists an estimated study-completion date in October 2027. That is not a promise that peer-reviewed results will appear on the same date.

Until those results and any regulatory action exist, do not tell a reader that tirzepatide has SELECT's exact evidence because weight loss was larger in another trial. Weight loss efficacy and cardiovascular-outcomes evidence are different questions.

What SELECT means if you're on Medicare

Answer capsule: Medicare now has two separate routes that can involve Wegovy. When Wegovy is prescribed for the FDA-approved cardiovascular MACE indication, the request goes through the member's Part D plan. The temporary Medicare GLP-1 Bridge, running July 1, 2026, through December 31, 2027, is a different weight-management route for eligible Part D beneficiaries who do not already have a Part D-covered GLP-1 indication. (CMS Bridge rules)

The average participant in SELECT was about 62. A big share of the people reading this page are on Medicare or headed there. There are two doors, and routing the prescription to the wrong one can waste weeks.

Door one: Part D under a covered medical indication

This is the route SELECT helped open for Wegovy. CMS's current Bridge prior-authorization form says a request should go to the patient's Part D plan when the drug is prescribed:

• To reduce major adverse cardiovascular events in an adult with established cardiovascular disease, or
• For another Part D-eligible diagnosis, such as type 2 diabetes, moderate-to-severe obstructive sleep apnea, or qualifying MASH, depending on the specific drug and label

For the Wegovy cardiovascular route, expect the plan to look for established cardiovascular disease, overweight or obesity, a covered formulary product, and whatever prior-authorization documentation that plan requires. Not every Part D plan handles the request the same way.

Door two: the Medicare GLP-1 Bridge

The Bridge is a separate CMS demonstration for weight management. It is active from July 1, 2026, through December 31, 2027 and operates outside the ordinary Part D benefit-payment flow.

Current Bridge facts:

• $50 copay for a one-month supply
• Covers Foundayo tablets, Wegovy injection and tablets, and Zepbound KwikPen
• Does not cover Zepbound single-dose vials or single-dose pens
• The Part D deductible does not apply
• The $50 does not count toward true out-of-pocket costs or the Part D out-of-pocket limit
• Extra Help does not lower the $50
• The Medicare Prescription Payment Plan cannot spread the copay across months
• The program is nationwide for eligible people with qualifying Medicare drug coverage

Who can qualify for the Bridge?

Medicare.gov says a person must be at least 18, have eligible Medicare drug coverage, not already receive the GLP-1 through Part D, and meet one of these starting criteria:

You are not eligible for the Bridge if your Part D plan already covers the GLP-1 or if you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or noncirrhotic MASH with moderate-to-advanced liver fibrosis that should route the medication through Part D instead. Your provider must prescribe a covered drug, certify participation in a lifestyle program focused on diet and exercise, and complete prior authorization when requested.

Which door first?

The clean rule is not “heart disease equals Door One, no heart disease equals Door Two.” It is:

1. If the prescription is for an FDA-approved Part D-covered indication, send it to the Part D plan. For this page, that includes Wegovy prescribed to reduce MACE in an adult with established cardiovascular disease and overweight or obesity.
2. If the prescription is only for weight management, Part D does not cover it, and the person meets the Bridge criteria, use the Bridge route.

That is the routing logic CMS put on the actual form.

→ Compare the Medicare Part D and GLP-1 Bridge pathways

What side effects showed up in SELECT?

Answer capsule: Adverse events caused 16.6% of the semaglutide group to permanently stop the trial product, compared with 8.2% on placebo, and gastrointestinal disorders accounted for much of the difference. Serious adverse events overall were reported in 33.4% versus 36.4%, but a lower aggregate serious-event rate does not erase contraindications, tolerability problems, or individual risk.

The number that matters most for tolerability

We're leading with discontinuation instead of a vague “generally well tolerated,” because it tells you how often an adverse event became serious enough in practical terms that the trial product was stopped.

16.6% versus 8.2%. An 8.4-percentage-point difference — roughly one additional adverse-event discontinuation for every twelve people assigned semaglutide rather than placebo.

The later safety analysis reported that gastrointestinal disorders caused treatment discontinuation in 10.0% with semaglutide versus 2.0% with placebo. Nausea, vomiting, diarrhea, constipation, and abdominal symptoms are familiar GLP-1 problems, often most noticeable during dose escalation.

The current label says that when a person does not tolerate a dose during injection escalation, the prescriber can consider delaying escalation for four weeks. That's a treatment conversation, not an instruction to change the schedule on your own.

Why “fewer serious adverse events” is true and still not a safety blank check

A later SELECT safety analysis found serious adverse events in 33.4% of the semaglutide group and 36.4% of placebo. The difference was driven partly by fewer serious cardiac disorders and other categories in the semaglutide group.

That can coexist with more gastrointestinal discontinuation because “serious adverse event” and “adverse event that made someone stop treatment” are different measurements. A person can stop over severe or persistent nausea without that event meeting the formal serious-adverse-event definition. A person can also have a cardiovascular hospitalization counted as serious.

Two different measurements. Both real. Neither one means the drug is safe for every particular person.

If you're 75 or older, read this part

Straight from the current FDA-approved labeling: in SELECT, hip and pelvis fractures were reported in 2.4% of Wegovy-treated participants age 75 or older versus 0.6% on placebo. Among women of all ages, the corresponding figures were 1.0% versus 0.2%. The label also says participants age 75 or older in both groups reported more serious adverse reactions overall than younger adults.

We looked. Many consumer explanations omit this. It's in the current label, it is relevant to a population with substantial older-adult representation, and leaving it out would tell you something about what kind of page this is.

The trial does not by itself explain the mechanism of the fracture imbalance or tell one person whether semaglutide caused a specific fracture. It does make age, fall risk, frailty, bone health, and concurrent medication reasonable clinician questions.

Contraindications and current warnings, briefly

Wegovy carries a boxed warning because semaglutide caused thyroid C-cell tumors in rodents. It is not known whether Wegovy causes those tumors in humans. Wegovy is contraindicated if you or a family member has had medullary thyroid carcinoma, if you have MEN 2, or if you have had a serious hypersensitivity reaction to semaglutide or a Wegovy ingredient.

The current prescribing information also includes warnings and precautions involving:

• Acute pancreatitis
• Acute gallbladder disease
• Hypoglycemia, especially with insulin or insulin secretagogues
• Acute kidney injury due to volume depletion
• Severe gastrointestinal adverse reactions; Wegovy is not recommended in severe gastroparesis
• Serious hypersensitivity reactions
• Diabetic retinopathy complications in people with type 2 diabetes
• Increased heart rate
• Pulmonary aspiration during general anesthesia or deep sedation because semaglutide delays gastric emptying

For the cardiovascular and weight-management indications, the label says to discontinue Wegovy when pregnancy is recognized, and to stop it at least two months before a planned pregnancy because of semaglutide's long half-life.

Tell any surgeon or anesthesiologist that you're taking it. Get the current warnings from the current prescribing information, not from an article. Including this one.

→ Build my medication-safety question list

What have later SELECT analyses added?

Answer capsule: Later SELECT papers have added information about long-term weight, kidney outcomes, heart failure, safety, hospital use, adiposity, and noninvasive liver-risk measures. They do not all carry the same evidentiary weight, so every result below is labeled by what was planned, what was exploratory, and what it still does not prove.

This is the part where a lot of coverage goes wrong. Every new paper gets reported like the original randomized primary result. They're not the same weight of evidence.

Here's our ladder, applied honestly:

The JAMA Cardiology “correction” did not change the hospitalization numbers

The hospitalization article carries a correction notice dated May 6, 2026. We opened it. The correction fixed the article's open-access status and license. It did not correct the event counts, hospitalization rates, or effect estimates.

That distinction matters because “the journal corrected the paper” sounds like a data problem when the published notice says it was a licensing problem. The hospitalization findings remain exploratory for the reasons in the table — not because their numbers were retracted or revised.

Why the evidence labels matter

• Prespecified means the analysis was defined before the relevant data were unblinded or analyzed. It does not automatically make an endpoint confirmatory.
• Confirmatory means the statistical plan controlled the false-positive risk so the result could support a formal claim.
• Supportive means the result adds context but was not given the same confirmatory status as the primary endpoint.
• Exploratory means the analysis is useful for learning and generating hypotheses but should not be promoted to the same certainty as the primary MACE result. An exploratory analysis can still be prespecified.
• Post hoc means the analysis was defined after seeing or learning from the data. That is different from “exploratory,” although an analysis can be both.

If you see a headline saying “SELECT proves semaglutide does X,” come back to this ladder and ask which rung X is standing on.

What should I ask my cardiologist or obesity-medicine clinician?

Answer capsule: The most useful question is not whether semaglutide is “good for the heart” in general. It is whether your cardiovascular history, baseline absolute risk, current treatment, formulation, tolerability, and coverage situation resemble the evidence closely enough to make the expected benefit worth pursuing for you.

Sixteen questions, organized by what they're actually for. Screenshot the ones that fit.

On whether the evidence fits you

1. Does my cardiovascular history match the kind SELECT directly studied — prior heart attack, prior stroke, or symptomatic peripheral artery disease?
2. If not, what evidence supports using Wegovy for my specific cardiovascular diagnosis?
3. Given my starting risk, is my likely absolute benefit larger or smaller than the crude SELECT average?
4. Is SELECT the most relevant trial for me, or does another cardiovascular-outcomes trial fit my situation better?

On my current cardiovascular medications

5. How would Wegovy fit with my statin, blood-pressure medication, antiplatelet therapy, and other cardiovascular treatment?
6. Which of my current medications stay exactly as they are? (SELECT added semaglutide on top of standard care.)
7. Does anything about my current cardiovascular status need evaluation before I start?

On safety and tolerability

8. Do I have a contraindication or warning that changes the benefit-risk calculation?
9. What is our plan if nausea, vomiting, diarrhea, constipation, or dehydration becomes hard to manage during escalation?
10. What are we monitoring, and how often?
11. Which symptoms mean I should call you, stop a dose, or seek urgent care?
12. I'm 75 or older, or I have fall or fracture risk — does the hip and pelvis fracture signal change your thinking?

On access

13. Which FDA-approved indication are you prescribing for, and does my documentation support it?
14. Is my cardiovascular diagnosis coded and documented in a way my plan will recognize?
15. What does my plan require for prior authorization, and who will submit it?
16. If the request is denied, will your office appeal, and what evidence will the appeal include?

→ Get my personalized SELECT appointment checklist

How we verified this page

Answer capsule: Every clinical number on this page comes from the primary SELECT publication, the current FDA prescribing information, a named peer-reviewed follow-up analysis, or an authoritative government source. The 1.5-point absolute difference, per-10,000 translation, and simple NNT are our arithmetic from the published event proportions, shown in full so you can check them.

What we checked, and when

What we calculated ourselves

We independently calculated:

• The crude absolute risk difference: 8.0% − 6.5% = 1.5 percentage points
• The crude event difference per 10,000 similar participants: 800 − 650 = 150
• The simple NNT estimate: 1 ÷ 0.015 = 66.7, rounded to about 67
• The adverse-event discontinuation difference: 16.6% − 8.2% = 8.4 percentage points, or roughly one additional discontinuation per 12 treated
• The crude relative difference from the reported proportions: 1 − (6.5 ÷ 8.0) = 18.75%
• The published hazard-based relative reduction: 1 − 0.80 = 20%

The NNT is a rough translation of the reported group proportions over mean follow-up, not a fixed-time Kaplan–Meier NNT, lifetime estimate, or prediction for one person.

What we did not do

We did not run SELECT. We did not independently audit participant-level data. We did not review anyone's medical records, determine anyone's FDA eligibility, predict anyone's personal cardiovascular benefit, or decide whether a medication is appropriate. We read the published documents, reconciled their definitions, and did arithmetic on published numbers.

Nobody with a medical license reviewed this page. We're not going to put a doctor's name on it to make it look like someone did.

Conflicts and easy-to-mix-up numbers we resolved or labeled

An honest evidence page shows its seams:

• Follow-up: The primary NEJM paper reports mean follow-up of 39.8 months. The current FDA label reports median follow-up of 41.8 months. Those are different statistics, and both can be correct. We label each one instead of swapping them.
• Participant count: The primary randomized report uses 17,604 participants. A baseline-characteristics publication reports 17,605 in its analysis set. We use 17,604 for the randomized trial result because that is the denominator tied to 8,803 and 8,801 in the primary report.
• Stopping treatment: 16.6% versus 8.2% is permanent discontinuation because of an adverse event. 30.6% versus 27.0% is the broader share that did not complete assigned treatment in the long-term analysis. Those are not interchangeable.
• Trial completion: Approximately 97.1% versus 96.8% completed trial follow-up. That does not mean the same share stayed on medication.
• Eligibility estimates: Published estimates of 4.47 million, 8.9 million, and 4.3 million US adults answer different questions with different definitions. We do not subtract them and call the remainder a measured population.
• The 2026 hospitalization correction: The correction changed the article's open-access status and license. It did not revise the hospitalization numbers.
• Cash prices: Several current manufacturer offers have stated expiration dates. The article shows those dates because an introductory price without its expiration is not a complete price.

Who paid for the trial

Novo Nordisk, which makes Wegovy, funded SELECT. That does not invalidate a randomized, double-blind, placebo-controlled result with a prespecified primary endpoint. It is a reason to check the protocol, hierarchy, event counts, FDA review, later analyses, and corrections instead of relying on a press release. That's what we did.

Who pays us

Weight Loss Provider Guide is an independent comparison and information resource for GLP-1 telehealth providers. We earn commissions from some providers linked on this site, including Ro. No provider paid for placement on this page, reviewed it before publication, or had input into how SELECT is described. We included NovoCare Pharmacy's lower-cost direct-pay route even though we do not earn a commission from it.

Corrections

Found a numerical, sourcing, or interpretation error? Email hello@weightlossproviderguide.com with the passage and the strongest source you have. Confirmed errors are corrected in the article and recorded in our corrections policy.

SELECT trial FAQ

Answer capsule: These are the short answers to the questions most likely to send someone back to search. The exact population, formulation, endpoint, timeframe, and evidence level still matter, so each answer keeps the boundary attached to the result.

What did the SELECT trial prove?

SELECT showed that, in adults age 45 or older with established cardiovascular disease, BMI of at least 27, and no diabetes, assignment to weekly subcutaneous semaglutide reduced the hazard of a first cardiovascular death, nonfatal heart attack, or nonfatal stroke by 20% compared with placebo on top of standard care. The reported event proportions were 6.5% versus 8.0% over mean follow-up of 39.8 months.

Why does the headline say 20% when 6.5% versus 8.0% looks like 18.75%?

The 20% figure comes from the time-to-event hazard ratio of 0.80: 1 − 0.80 = 20%. The crude proportion calculation is 1 − (6.5 ÷ 8.0) = 18.75%. They use different statistical approaches, so both numbers can be mathematically defensible.

How many people were in the SELECT trial?

17,604 adults were randomized: 8,803 to semaglutide and 8,801 to placebo. The trial was conducted at 804 sites in 41 countries, with enrollment from October 2018 through March 2021.

How long did the SELECT trial last?

Mean follow-up in the primary publication was 39.8 months, or about 3.3 years. The current FDA label reports median follow-up of 41.8 months. Individual follow-up varied because enrollment occurred over several years and the event-driven trial ended on a common schedule.

What was the absolute risk reduction?

Using the reported crude event proportions, the absolute difference was 1.5 percentage points: 8.0% on placebo minus 6.5% on semaglutide.

What was the number needed to treat?

A simple calculation gives about 67 similar people treated for one first major cardiovascular event avoided over the study period: 1 ÷ 0.015 = 66.7. That is a rough translation from raw group proportions, not a fixed-time or personalized NNT.

Did the SELECT trial include people with diabetes?

No. Type 1 and type 2 diabetes were exclusion criteria, and a screening A1c at or above the protocol threshold also excluded enrollment. SELECT was designed to test cardiovascular outcomes in people with overweight or obesity and established cardiovascular disease without diabetes.

Did semaglutide reduce cardiovascular death on its own?

The point estimate favored semaglutide: 2.5% versus 3.0%, hazard ratio 0.85. But the 95% confidence interval crossed 1.0, the P value was 0.07, and the endpoint did not meet its allocated confirmatory threshold. It was not a formally confirmed standalone finding.

Did semaglutide reduce heart attacks?

Fatal or nonfatal myocardial infarction occurred in 2.8% of the Wegovy group and 3.8% of the placebo group, hazard ratio 0.72. That was a favorable component result, but it was not one of the endpoints protected by the same confirmatory testing hierarchy as the primary MACE result.

Did semaglutide reduce strokes?

Fatal or nonfatal stroke occurred in 1.8% versus 2.0%, hazard ratio 0.89, with a 95% confidence interval of 0.72 to 1.11. The point estimate favored Wegovy, but the interval included no difference.

Did most participants drop out?

No. Approximately 97.1% of the semaglutide group and 96.8% of the placebo group completed trial follow-up. A larger share did not complete assigned treatment—30.6% versus 27.0%—and adverse events caused 16.6% versus 8.2% to permanently stop the trial product.

Why were there so few people left under some four-year charts?

Only participants enrolled early enough could reach week 208 before the common end of the event-driven trial. Other reasons for a missing week-208 measurement included stopping medication while remaining in outcome follow-up and missing a specific weigh-in. The smaller landmark denominator is not the same thing as the number who left the trial.

How much weight did people lose?

At week 104, mean weight change was approximately −9.4% with semaglutide versus −0.9% with placebo. The prespecified long-term analysis estimated in-trial change of approximately −10.2% versus −1.5% at week 208, using multiple imputation for missing observations.

Does the cardiovascular benefit depend on losing a lot of weight?

A prespecified 2025 analysis found that the MACE benefit was not confined to participants with the highest starting BMI or greatest measured weight loss, and estimated that change in waist circumference mediated about one-third of the effect. That does not prove a completely weight-independent mechanism or predict an individual benefit when little weight is lost.

Was SELECT a Wegovy trial or an Ozempic trial?

SELECT directly tested once-weekly subcutaneous semaglutide titrated toward 2.4 mg—the injection regimen sold as Wegovy. It was not an Ozempic trial. Ozempic uses different labeled doses and has its own cardiovascular evidence and indications in people with type 2 diabetes.

Does SELECT apply to Wegovy tablets?

Not directly. The current Wegovy label includes tablets under the cardiovascular indication, but SELECT itself tested the weekly injection. The tablet's approval rests on a broader evidence and regulatory package than SELECT alone.

Does SELECT apply to compounded semaglutide?

No. SELECT tested an FDA-approved manufactured product. Compounded semaglutide is not FDA-approved, is not reviewed before marketing for safety, effectiveness, or quality in the same way, and has no direct cardiovascular-outcomes evidence from SELECT.

Does SELECT apply to Zepbound or tirzepatide?

No. Tirzepatide is a different drug. SURPASS-CVOT in people with type 2 diabetes and established atherosclerotic cardiovascular disease showed tirzepatide was noninferior—but not superior—to dulaglutide for MACE, with 12.2% versus 13.1% and a hazard ratio of 0.92. The placebo-controlled SURMOUNT-MMO trial in people with obesity or overweight without diabetes has an estimated primary completion in October 2027.

Is it too late if I already had a heart attack?

No. SELECT was specifically a secondary-prevention trial in people with established cardiovascular disease, and about 76% had a prior myocardial infarction. Prior stroke and symptomatic peripheral artery disease were other qualifying routes.

Can Wegovy replace my statin, aspirin, blood-pressure medication, or other heart treatment?

No conclusion in SELECT supports replacing standard cardiovascular treatment. At baseline, about 90% used lipid-lowering therapy, 86% antiplatelet therapy, 74% an ACE inhibitor or ARB, and 70% a beta blocker. The primary result was measured on top of that care.

Did FDA approve Wegovy because of SELECT?

On March 8, 2024, FDA approved Wegovy to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in adults with established cardiovascular disease and either obesity or overweight, together with a reduced-calorie diet and increased physical activity. SELECT supplied the central cardiovascular-outcomes evidence for that action.

Does the FDA label match SELECT's entry criteria exactly?

No. SELECT required age 45 or older, BMI of at least 27, and one of three specified routes to established cardiovascular disease, while excluding diabetes. The current adult indication says established cardiovascular disease and either obesity or overweight without restating every SELECT entry criterion. The label, trial population, and a payer's coverage rules are three separate layers.

Is Medicare covering Wegovy now?

Medicare Part D can cover Wegovy when it is prescribed for the FDA-approved cardiovascular indication and the plan's formulary and prior-authorization rules are met. From July 1, 2026, through December 31, 2027, the separate Medicare GLP-1 Bridge also covers specified GLP-1 products for beneficiaries who meet its BMI and medical criteria, with a $50 monthly copay that does not count toward the deductible, TrOOP, the Medicare Prescription Payment Plan, or Extra Help reductions.

What was corrected in the 2026 JAMA Cardiology hospitalization paper?

The May 6, 2026 correction changed the article's open-access status and license. It did not change the hospitalization event counts, rates, or effect estimates.

Where was the SELECT trial published?

The primary report by Lincoff and colleagues was published online by the New England Journal of Medicine on November 11, 2023, and appeared in the December 14, 2023 issue. The trial is registered as NCT03574597.

Sources

1. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563.
2. US Food and Drug Administration. Current Wegovy Prescribing Information, revised February 2026.
3. US Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight, March 8, 2024.
4. Ryan DH, Lingvay I, Deanfield J, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine. 2024. doi:10.1038/s41591-024-02996-7.
5. Deanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. The Lancet. 2025. doi:10.1016/S0140-6736(25)01375-3.
6. Perkovic V, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nature Medicine. 2024.
7. Kosiborod MN, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet. 2024.
8. Lingvay I, et al. Safety profile of semaglutide versus placebo in the SELECT study. Obesity. 2025.
9. Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease. JAMA Cardiology. 2026.
10. Correction to the SELECT hospitalization article. JAMA Cardiology. May 6, 2026.
11. Semaglutide, liver-risk indices, and cardiovascular outcomes in SELECT. Nature Medicine. 2026.
12. American College of Cardiology. SELECT: Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity.
13. ClinicalTrials.gov. SELECT, NCT03574597.
14. Lusk JB, et al. Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial. American Heart Journal.
15. Aggarwal R, et al. Semaglutide Eligibility Across All Current Indications for US Adults. JAMA Cardiology.
16. Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge and information for providers.
17. Medicare.gov. Weight-loss drug coverage through the Medicare GLP-1 Bridge.
18. Novo Nordisk. Wegovy Price Guide, April 2026.
19. Ro. Ro Body Program pricing and GLP-1 Insurance Coverage Checker.
20. US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss, semaglutide shortage resolution, and 2026 proposed 503B bulks-list action.
21. Nicholls SJ, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025; and ClinicalTrials.gov, SURMOUNT-MMO, NCT05556512.
22. Public reader questions used only for voice-of-customer language: r/medicine discussion and r/WegovyWeightLoss discussion.

Version 1.1 · Data cutoff August 3, 2026

Found an error? Email hello@weightlossproviderguide.com with the passage and the primary source. Confirmed corrections are fixed in the article and logged in our corrections policy.

This article explains published research. It is not medical advice, a diagnosis, or a recommendation to start, stop, or change treatment. Only a clinician who knows your history can tell you whether a medication or any part of this evidence applies to you.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

→ Get my personalized GLP-1 action plan

A few questions about your goals, insurance, and where you're starting. It doesn't diagnose or prescribe anything. It points you toward the path that fits.